Amid the global pandemic, one silver lining may be consumers’ desire to refocus on health and wellness. For many people, that means lacing up some running shoes—good news for athletic brands, especially those that have pivoted easily to online sales.

Nike stock (ticker: NKE) should be one of the major beneficiaries of this trend, argues Raymond James analyst Matthew McClintock. He reiterated an Outperform rating on Nike Wednesday, while raising his target for the stock price by $15, to $115.

Nike, he says, “continues to demonstrate ample demand for strong, innovative product in the marketplace, despite the Covid-19 challenge.”… READ MORE @ Barrons

Tags: